臨床研究等提出・公開システム

A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients with Solid Tumors Likely to Express CLDN18.2 (ELVCAP-002-01)

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 (ELVCAP-002-01)

Kroll Stew

Elevation Oncology, Inc.

101 Federal Street, Suite 1900, Boston, MA, United States

skroll@concentrabiosciences.com

Kobayashi Yoshikazu

Medpace Japan K.K.

1-5-8, Jingumae, Shibuya-ku, Tokyo

+81-3-4563-7000

RSJapan1@medpace.com

Complete

Feb. 16, 2024

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

- Availability of tumor tissue (archived and fresh tumor biopsy, if medically feasible)
- Select advanced or metastatic solid tumor that is likely to express CLDN18.2 such as gastric/GEJ, pancreatic and esophageal cancer
- >= 18 years of age
- ECOG performance status (PS) 0 or 1 at Screening
- Progressed on or after standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy
- Have at least one measurable extra-cranial lesion as defined by RECIST v1.1
- Adequate organ function
- Life expectancy > 12 weeks
- Ability to understand the nature of this study, comply with protocol requirements, and give written informed consent
- Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following study completion

- Pregnant or breastfeeding
- Symptomatic or untreated brain metastases
- Have previously received CLDN18.2 antibody drug conjugates (ADCs) or any ADC containing an auristatin payload (prior monoclonal antibody against CLDN18.2 may be eligible)
- Have peripheral neuropathy Grade >= 2
- Have history of non-infectious pneumonitis/interstitial lung disease
- Have diagnosis of another malignancy, or history of systemic treatment for invasive cancer within last 3 years. Note: Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. Diagnosis of non-melanoma skin cancer, carcinoma in situ of the cervix or breast, or noninvasive tumor does not affect eligibility
- Have active ocular surface disease at baseline (based on screening ophthalmic examination)
- Have serious concurrent illness or clinically relevant active bacterial, fungal or viral infection
- Have previous hypersensitivity to any known components of EO-3021 or history of severe infusion reaction or hypersensitivity (CTCAE Grade 3 or higher) with monoclonal antibody treatment
- Clinically significant cardiac disease, including but not limited to symptomatic congestive heart failure, unstable angina, acute myocardial infarction within 6 months of planned first dose, or unstable cardiac arrhythmia requiring therapy (including torsades de pointes)
- Have history of allogenic hematopoietic stem cell transplantation or solid organ transplantation with ongoing systemic immunosuppressive therapy
- Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the Investigator

Both

Solid Tumor

EO-3021 is administered intravenously once (1.0 to 2.9 mg/kg) every 3 weeks.

1. The incidence rate of dose limiting toxicities (DLT) during the first 21-day cycle of EO-3021 treatment
2. Number of patients with treatment emergent adverse events
3. Number of patients with serious adverse events
4. Number of patients with clinically significant changes to vital signs
5. Number of patients with clinically significant changes in laboratory tests

+81-3-3542-2511

Jan. 17, 2024

No

United States/South Korea